Skip to main content
PERCHERON THERAPEUTICS LIMITED logo

PERCHERON THERAPEUTICS LIMITED — Investor Relations & Filings

Ticker · PER ISIN · AU0000317281 LEI · 984500FF63A961E0K787 ASX Professional, scientific and technical activities
Open in API
Filings indexed 1,206 across all filing types
Latest filing 2019-09-01 Regulatory Filings
Country AU Australia
Listing ASX PER

About PERCHERON THERAPEUTICS LIMITED

https://percherontx.com

Percheron Therapeutics Limited is a clinical-stage company focused on the development of novel antisense pharmaceuticals for rare diseases. The company's lead program, ATL1102, is an antisense oligonucleotide targeting the CD49d receptor, a subunit of the VLA-4 integrin. This therapeutic candidate is primarily being developed for the treatment of Duchenne muscular dystrophy (DMD), where it aims to reduce inflammation and muscle damage by modulating the immune system's response. Formerly known as Antisense Therapeutics, the firm utilizes its proprietary antisense technology platform to create targeted therapies that inhibit the production of proteins associated with disease progression. The company's research and development efforts are centered on addressing significant unmet medical needs through precision genetic medicine.

Recent filings

Filing Released Lang Actions
ATL1102 for DMD European regulatory interactions 2 pages 166.8KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 2 September 2019 from Antisense Therapeutics regarding the commencement of European regulatory interactions for the clinical development of ATL1102 in Duchenne Muscular Dystrophy (DMD). It discusses planned meetings with regulatory authorities, trial design, and development path but does not contain financial data, earnings, or detailed financial reports. It is a regulatory update about clinical trial progress and regulatory strategy rather than a financial report or earnings release. The document is relatively short (6275 characters) and serves as a corporate announcement about regulatory interactions. Therefore, it fits best under Regulatory Filings (RNS), which is the fallback category for miscellaneous regulatory announcements that do not fit other specific categories.
2019-09-01 English
Appendix 4E and Full Year Statutory Accounts 74 pages 936.1KB
Annual Report Classification · 100% confidence The document is titled 'Antisense Therapeutics Limited Appendix 4E Audited Financial Report Year Ended 30 June 2019' and includes detailed financial results, an operations report, directors' report, auditor's report, consolidated financial statements, and notes. It covers the full fiscal year ended 30 June 2019 and contains comprehensive financial data and analysis. The presence of an independent auditor's report and detailed financial statements confirms this is a full annual report. The document length is substantial (15,000 characters), and it is not merely an announcement of a report but the report itself. Therefore, the document fits the definition of an Annual Report (10-K). FY 2019
2019-08-29 English
Acromegaly Early Access Program Status Update 2 pages 155.9KB
Regulatory Filings Classification · 95% confidence The document is a status update regarding the Acromegaly Early Access Program by Antisense Therapeutics Limited. It discusses clinical development progress, regulatory challenges, and strategic focus on drug development programs. There are no financial statements, earnings data, or detailed financial analysis present. The document is an announcement providing information about the status of a clinical program and company strategy rather than a formal financial report or regulatory filing. It does not fit into categories like Annual Report, Interim Report, Earnings Release, or Audit Report. It is also not a call transcript, board management change, or capital update. The content is primarily an operational update related to clinical development and regulatory status, which is best classified under Regulatory Filings (RNS) as a general regulatory announcement and update that does not fit other specific categories.
2019-08-25 English
Change in substantial holding 5 pages 267.2KB
Major Shareholding Notification Classification · 100% confidence The document is a Form 604 Notice of change of interests of substantial holder under the Corporations Act 2001 Section 671B. It details changes in voting power and shareholdings of Platinum Investment Management Limited in Antisense Therapeutics Limited. The document is a regulatory disclosure about substantial shareholding changes, not a financial report, earnings release, or management report. It fits the definition of a Major Shareholding Notification (MRQ) as it notifies changes in significant share ownership levels crossing thresholds.
2019-07-30 English
Phase II DMD clinical trial on track for dosing completion 2 pages 107.9KB
Regulatory Filings Classification · 95% confidence The document is an ASX announcement dated 24 July 2019 from Antisense Therapeutics Limited. It provides an update on the progress of a Phase II clinical trial for a drug (ATL1102) targeting Duchenne Muscular Dystrophy (DMD). The content focuses on clinical trial progress, patient dosing completion, safety data (no serious adverse events), and expected timing for reporting trial results. There are no financial statements, regulatory certifications, or detailed financial performance data. The document is a progress update on clinical trial activities rather than a financial report or regulatory filing. It is not a full annual or interim report, nor an earnings release. The document is a company announcement providing operational and clinical trial progress information, which fits best under the category of a Regulatory Filing (RNS) as a general regulatory announcement that does not fit other specific categories.
2019-07-23 English
Appendix 4C - quarterly 5 pages 209.1KB
Interim / Quarterly Report Classification · 100% confidence The document is titled 'Appendix 4C Quarterly report for entities subject to Listing Rule 4.7B' and contains detailed consolidated statement of cash flows for the current quarter and year to date, along with notes on payments to directors, financing facilities, estimated cash outflows for the next quarter, and compliance statements. The document is approximately 9403 characters long, which is substantial and contains actual financial data and analysis for a quarterly period ending 30 June 2019. The presence of detailed financial statements and cash flow data for a quarter aligns with the definition of an Interim / Quarterly Report (IR). It is not merely an announcement or a certification, but a substantive financial report. Therefore, the correct classification is IR (Interim / Quarterly Report). Q4 2019
2019-07-17 English

Browse filings by year

25 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.